Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly

Shuqian Liu, Daphne T. Adelman, Yaping Xu, Jillone Sisco, Susan M. Begelman, Susan M. Webb, Xavier Badia, Tina K. Thethi, Vivian Fonseca, Lizheng Shi

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)


© 2018 American Federation for Medical Research (unless otherwise stated in the text of the article). All rights reserved. The study aimed to assess the economic burden, health-related quality of life (HRQoL), and acromegaly treatment satisfaction in the USA. A web-based, cross-sectional survey was distributed to members of Acromegaly Community. Data related to comorbidities, treatment patterns, and treatment satisfaction were collected. The costs over the past 3 months included out-of-pocket cost, sick leave, leave of absence, direct loss of job due to acromegaly, unemployment, assistance to perform household chores, and family member loss of income. The HRQoL was assessed by Acromegaly Quality of Life (AcroQoL) and EQ-5D-3L questionnaires. Among 106 patients who completed the survey (mean age: 46 years, female: 76.4%), 44.3% presented with ≥5 comorbidities, and 90.6% reporting acromegaly-related symptoms. Compared with the low-symptom group 0-3 (n=41), the 4+ symptoms group (n=65) was more likely to have depression (OR=2.3, 95% CI 1.1 to 5.2) and cardiovascular disease (OR=5.8, 95% CI 2.0 to 16.7), and experienced higher costs (loss of job: $8874 vs $1717, P=0.02; unemployment disability: $17,102 vs $429, P=0.003; household chores: $2160 vs $932, P=0.0003; family members' income loss: $692 vs $122, P=0.03). The high-symptom group had lower HRQoL scores, compared with the low-symptom group (EQ-5D-3L: 0.53 vs 0.75, P<0.0001; AcroQoL: 27 vs 56, P<0.0001). Only 55.7% among patients requiring injections for acromegaly were satisfied. Patients with acromegaly who presented with multiple acromegaly-related symptoms were evidenced to have experienced higher economic burden and poorer quality of life than patients with the same diagnosis but fewer symptoms. The low rate of treatment satisfaction warrants need for further studies.
Original languageEnglish
Pages (from-to)653-660
JournalJournal of Investigative Medicine
Issue number3
Publication statusPublished - 1 Mar 2018


  • endocrinology
  • pituitary diseases
  • pituitary-adrenal system
  • rare diseases


Dive into the research topics of 'Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly'. Together they form a unique fingerprint.

Cite this